Gene Therapy: How a New Cure for Blindness Reverses Retinal Dystrophy

Thursday, October 12, 2017

A Food and Drug Administration committee has voted that a gene therapy touted as a breakthrough for people with a particular genetic form of blindness is effective. A final FDA approval for the treatment, Luxturna, would be a landmark event for gene therapy and for sufferers of this inherited disorder. Whether this is the first gene therapy to get this close to FDA approval depends on your definition of “gene therapy.” FFB's chief research officer, Steve Rose, weighed in on the definition and more to Newsweek. Read what Steve had to share on the therapy and how FFB funded prelimary research here.